Syrma Johari MedTech Limited, a subsidiary of Syrma SGS Technology Limited, has inaugurated a new Medical Plastics and Precision Molding Facility in Jodhpur, Rajasthan. This significant expansion, spanning over 120,000 sq. ft., enhances the company’s integrated MedTech manufacturing capabilities, including injection molding, extrusion, and tooling. The facility aims to support the growing global demand for precision medical components and specialized tubing.
Syrma SGS Technology Expands MedTech Footprint
Syrma SGS Technology Limited announced today the inauguration of a new, state-of-the-art Medical Plastics and Precision Molding Facility by its subsidiary, Syrma Johari MedTech Limited. Located in Jodhpur, Rajasthan, this facility marks a significant milestone in the company’s strategic expansion within the MedTech sector.
Key Facility Highlights
- Area: The new plant covers an expansive area of over 120,000 sq. ft.
- Capabilities: The facility is equipped for a comprehensive range of processes including medical plastics and precision molding, injection molding, extrusion, blow molding, and tooling.
- Product Focus: It is designed to manufacture precision medical components, multi-cavity parts, tight-tolerance molded components, medical and diagnostic tubing, and customized tubing profiles.
Strategic Importance
This expansion strengthens Syrma SGS Group’s broader manufacturing ecosystem, which includes 17 global production sites and four design and innovation centers. The Jodhpur facility is poised to enhance Syrma Johari MedTech’s position as a design-led global MedTech CDMO, offering end-to-end solutions from design and engineering to manufacturing and regulatory compliance. The company aims to cater to the evolving needs of the global MedTech industry, supporting programs in diagnostics, medical aesthetics, patient monitoring, surgical care, and critical care.
Sandeep Tandon, Executive Chairman of Syrma SGS Technology Limited, highlighted the facility’s importance, stating, “The inauguration of the Jodhpur facility marks an important milestone in the evolution of our MedTech capabilities and reflects our long-term commitment to building specialised, high-value manufacturing capabilities in India in this industry.”
Source: BSE
